Navigation Links
MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
Date:3/14/2013

KENNESAW, Ga., March 14, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Musculoskeletal Conference in Chicago.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor , President and COO, and Michael J. Senken , Chief Financial Officer, are scheduled to present on March 19th at 3:20 p.m. CDT/4:20 p.m. EDT at the Westin Michigan Avenue.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 130,000 allografts to date to distributors and OEMs for application in the Wound Care, Surg
'/>"/>

SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
2. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
3. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
4. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
5. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
6. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
7. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
8. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
9. MiMedx Group Announces Record Second Quarter Results
10. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
11. MiMedx Group Announces Record First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research conducted by ... presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL showed ... increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took longer ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... than EUR 1.022 billion in 2013; while production volume reached close to 1.84 ... producing country with a share of 75.5% of the region’s total aluminium hydroxide ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Preventing Storm Surge Flooding in Houston 2Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... Published in the ... Academy of Sciences, MOUNTAIN VIEW, Calif., Sept. 26 ... developing,and commercializing therapeutics that target the chemokine system, today,announced ... experiments to,elucidate CXCR7,s essential role in the progression and ...
... Dana C. Hilt Named SVP, Clinical Development & ... EnVivo Pharmaceuticals,Inc., a privately held biopharmaceutical company ... of Dr. Dana C.,Hilt as Senior Vice President ... coordinating all pre-clinical and clinical development,activities of EnVivo,s ...
... Materials for Food and Other Packaging Uses, ... (NYSE: DD ) and Plantic Technologies Limited, ... plans to,collaborate in the development and sale of ... include the collaborative development of new, renewably sourced,resins ...
Cached Biology Technology:ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 2ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 4ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 5EnVivo Pharmaceuticals Announces Executive Appointment 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 3
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... perennially covered in ice. It is exposed to severe ... and, during the winter, 24-hour darkness. But, for the ... To study them, Dr. Rachel Morgan-Kiss from the University ... to sample the ice-covered lake. The article describing her ...
... 2012 Researchers at the Hebrew University of Jerusalem and ... that produce very abundant biochemical products in the cell and ... flexible subset that might have abnormal function in a disease. ... found among various organisms and cell types, including stem cells ...
... Africa could benefit from access to treatment for an endemic ... of infection. Researchers tested hundreds of children aged between ... fever also known as bilharzia or schistosomiasis is ... they are perceived to be at low risk of exposure ...
Cached Biology News:Research on carbon-consuming life-forms in Antarctica published in JoVE 2Treatment to benefit African infants at risk of endemic fever 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The ProteinChip beta-amyloid Multipeptide Kit, ... Systems, makes detecting a variety of ... than ever before. - Clinical neuroscience ... after drug treatment - Correlate beta-amyloid ...
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: